GE HealthCare to Acquire icometrix for AI-Powered Brain MRI Solutions
GE HealthCare has entered into an agreement to acquire icometrix, a Belgium-based company specializing in AI-driven brain imaging analysis for neurological disorders including Alzheimer’s disease. The deal is intended to expand GE HealthCare’s neurology portfolio by integrating icometrix’s icobrain platform into its MRI systems, enhancing quantitative MRI assessment and clinical decision support.
Founded in 2011 in Leuven, Belgium, icometrix has established its platform across hospitals worldwide and collaborates with pharmaceutical companies in drug development, clinical trials, and real-world evidence generation. The company’s solutions are designed to provide longitudinal insights from MRI scans, improving diagnosis, treatment planning, and operational efficiency in neurology.
icometrix has also been recognized by the American College of Radiology with the Transparent AI badge. Its icobrain platform is also reportedly supported by more than 270 peer-reviewed publications and is integrated into daily workflows at hospitals and research institutions.
icometrix’s icobrain suite provides tools to compare and quantify brain MR scans across conditions such as multiple sclerosis, dementia, epilepsy, stroke, and traumatic brain injury. Its icobrain aria product is reportedly the first FDA 510(k)-cleared AI solution for detecting Amyloid Related Imaging Abnormalities (ARIA), known side effects of anti-amyloid therapies used in Alzheimer’s treatment. The platform enables radiologists to identify both ARIA-E (edema) and ARIA-H (hemorrhage), track their progression, and support monitoring of patients over the course of therapy.
GE HealthCare plans to distribute and integrate icobrain aria broadly across vendor MRI systems while combining it with its own MR technologies such as AIR Recon DL and SONIC DL 3D. This integration is aimed at managing growing MRI demand as new Alzheimer’s therapies are adopted globally. Studies cited by the Alzheimer’s Association estimate the number of adults living with Alzheimer’s disease could double by 2050, with MRI playing a key role in eligibility assessment and side effect monitoring.
GE HealthCare’s portfolio includes MR and CT scanners, ultrasound systems, interventional devices, diagnostic imaging agents, and more than 200 software applications. GE HealthCare reportedly currently leads the FDA list of AI-enabled medical device authorizations, with 100 clearances over the past four years across oncology, cardiology, and neurology.
Financial terms of the acquisition were not disclosed. The transaction remains subject to regulatory approvals and customary closing conditions, with GE HealthCare intending to fund it using cash on hand.
Topics: Startups & Deals
